© Springer International Publishing Switzerland 2016David S. Cooper and Cosimo Durante (eds.)Thyroid Cancer10.1007/978-3-319-22401-5_32 32. RAI-Refractory Differentiated Thyroid Cancer with Multiple Organ Progressive Disease Steven I. Sherman1 (1) University of Texas MD Anderson Cancer Center, Unit 1461, 301402,…
Fig. 30.1 Upper left: non-contrast-enhanced CT showing right paratracheal mass (white arrow). Lower left: 18FDG-PET-CT showing right paratracheal recurrent tumor (white arrow). Upper right: 18FDG uptake with a standard uptake…
Fig. 29.1 Pretreatment I-123 scan in a patient with low-risk papillary thyroid cancer, idiopathic hyperprolactinemia, and mild galactorrhea demonstrating bilateral breast uptake. The decision was made not to treat this…
© Springer International Publishing Switzerland 2016David S. Cooper and Cosimo Durante (eds.)Thyroid Cancer10.1007/978-3-319-22401-5_23 23. A Case of Papillary Thyroid Cancer Without Aggressive Histological Features with Nodal Metastases in an Older Patient Maria Grazia Castagna1, 2, Lucia Brilli1, 2…
© Springer International Publishing Switzerland 2016David S. Cooper and Cosimo Durante (eds.)Thyroid Cancer10.1007/978-3-319-22401-5_22 22. A Case of Papillary Thyroid Cancer Without Aggressive Histological Features with Nodal Metastases Detected During Follow-Up in a Younger Patient Maria Grazia Castagna1,…
© Springer International Publishing Switzerland 2016David S. Cooper and Cosimo Durante (eds.)Thyroid Cancer10.1007/978-3-319-22401-5_21 21. A Patient with Postsurgical Recurrent Laryngeal Nerve Damage and Nerve Monitoring David L. Steward1 and Adam D. Goodale1 (1) Department of Otolaryngology – Head &…
-hydroxylated vitamin D analogues, most patients with hypoparathyroidism have been shifted to treatment with either alfacalcidol or calcitriol, as the plasma half-life of activated vitamin D metabolites is much shorter…
Risk from T4 therapy Response to therapy Excellent (mU/L) Indeterminate (mU/L) Biochemically incomplete (mU/L) Structurally incomplete (mU/L) Minimal 0.5–2.0a 0.1–0.5 <0.1 <0.1 Moderate 0.5–2.0a 0.5–2.0a 0.1–0.5 <0.1 High 0.5–2.0a 0.5–2.0a…
Features Sensitivity (%) Specificity (%) NPV (%) PPV (%) Accuracy (%) Prevalence (%) in normal LNs Suspicious for malignancy Punctate hyperechogenicity 5–69 93–100 33–60 88–100 56–72 0 Cystic aspect 10–34…
Fig. 14.1 Overall survival is significantly better in patients demonstrating a biochemical incomplete response to therapy than patients demonstrating a structural incomplete response to therapy (Kaplan–Meier analysis, p < 0.0001) (Adapted from…
